Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanny B Aragon-Ching

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Cardiovascular disease with androgen deprivation: the (forgotten) role of testosteroneJeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Active surveillance for prostate cancer: has the time finally come?Jeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?Jeanny B Aragon-Ching
Frontiers in Oncology|November 12, 2014
The evolution of prostate cancer therapy: targeting the androgen receptorJeanny B Aragon-Ching
Nature Reviews. Urology|July 7, 2021
Pembrolizumab use in bladder cancer: a tale of two trialsJeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?Jeanny B Aragon-Ching
Asian Journal of Andrology|June 29, 2019
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancerJeanny B Aragon-Ching
Chinese Clinical Oncology|April 10, 2023
Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer?Jeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate CancerJeanny B Aragon-Ching
Nature Reviews. Urology|January 12, 2021
The emerging role of checkpoint inhibitors for rare genitourinary cancersJeanny B Aragon-Ching
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Cardiovascular disease with androgen deprivation: the (forgotten) role of testosteroneJeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Active surveillance for prostate cancer: has the time finally come?Jeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?Jeanny B Aragon-Ching
Frontiers in Oncology|November 12, 2014
The evolution of prostate cancer therapy: targeting the androgen receptorJeanny B Aragon-Ching
Nature Reviews. Urology|July 7, 2021
Pembrolizumab use in bladder cancer: a tale of two trialsJeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2019
Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?Jeanny B Aragon-Ching
Asian Journal of Andrology|June 29, 2019
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancerJeanny B Aragon-Ching
Chinese Clinical Oncology|April 10, 2023
Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer?Jeanny B Aragon-Ching
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2016
Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate CancerJeanny B Aragon-Ching
Nature Reviews. Urology|January 12, 2021
The emerging role of checkpoint inhibitors for rare genitourinary cancersJeanny B Aragon-Ching
Pageof 15